Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

GLP-1 RAs used by adults with type 2 diabetes and obesity is linked to lower risk for dementia, stroke, and mortality vs ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

HealthDay News — For adults with overweight or obesity, certain factors might influence weight loss after taking glucagon-like peptide 1 receptor agonists (GLP-1 RAs), according to a study published ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with peripheral artery disease.

Novo Nordisk said on Monday the European drugs regulator will allow a label update for its diabetes drug Ozempic to include a condition called peripheral artery disease.

Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with ...

Conclusions Cagrilintide–semaglutide provided significant and clinically relevant body-weight reductions in adults with overweight or obesity, as compared with placebo.